Cytek Biosciences FY Conference Summary Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Cell analysis, specifically focusing on flow cytometers - **Growth Recognition**: Named one of the leading growth companies in the U.S. by Time Magazine [2][4] Key Financial Metrics - **Revenue**: $201.5 million in FY 2025, representing a 1% growth year-over-year despite a 4% decline in the overall flow cytometry market [4][11] - **Cash Position**: $261.5 million since going public, with positive cash flow generation [4][5] - **Market Share**: Cytek outperformed the market by gaining market share during a period of overall market decline [4][11] Product Launches and Innovations - **New Products**: - **Aurora Evo**: Launched in 2025, received positive feedback and is now a dominant product in sales [21][17] - **Muse Macro**: Awarded the BioTech Breakthrough Award of 2025 [2] - **Product Portfolio**: Broad range of instruments and reagents, including high-end products like Aurora Evo and CellSorter, and mid-level applications like Northern Lights and Muse Micro [12][17] Market Dynamics - **Flow Cytometry Market**: Estimated to grow from $5 billion to $9.2 billion by 2032, with a CAGR of 8.8% [11] - **Geographic Revenue Distribution**: - 47% from the U.S. - 28% from APAC - 25% from the rest of the world [7] - **Regional Growth**: APAC is expected to grow faster than the U.S., with government incentives driving investment in China [33] Customer Segments - **Revenue by Industry**: - 58% from pharma, biotech, and CROs - 42% from academic and government sectors [8] - **Customer Base**: Approximately 3,000 unique institutions and over 24,000 users on Cytek Cloud [3][14] Future Growth Drivers - **Service and Reagents**: Expected to grow at rates consistent with 2025, with a target of increasing recurring revenue from 34% to 40% over the next few years [17][24] - **Clinical Applications**: Expansion in Europe and China, with partnerships to drive clinical adoption [15][19] - **Installed Base**: Growing installed base is expected to generate consistent revenue growth [40] Challenges and Market Sentiment - **Funding Concerns**: Academic and government markets faced funding cuts, but sentiment has improved compared to the previous year [26][29] - **Pharma Spending**: While there were contractions in 2025, a return to growth is anticipated in 2026 as funding is reevaluated [28][30] Conclusion - **Strategic Positioning**: Cytek is well-positioned to capitalize on market growth through innovation, geographic expansion, and a diversified customer base. The company continues to outperform the market and is expected to maintain its growth trajectory in the coming years [10][39]

Core Insights - Cytek Biosciences reported a record fourth-quarter revenue of $62.1 million, representing an 8% year-over-year increase, attributed to stabilization in the U.S., growth in the E.U., and strong performance in APAC [3][6] - The company ended 2025 with a net loss of $44.1 million, which included a significant non-cash deferred tax valuation allowance [5][13] - Cytek initiated 2026 revenue guidance of $205–212 million, assuming improved market conditions in EMEA and the U.S., along with continued growth in service and reagents [4][16] Revenue Growth - EMEA revenue grew 21% in Q4, driven by services and instruments for academic and government customers, while U.S. revenue grew 5% with double-digit service revenue growth [1][2] - The company experienced double-digit year-over-year revenue growth in both EMEA and APAC during Q4, with mid-single-digit growth in the U.S. [2] Profitability and Margins - GAAP gross margin fell to 53% in Q4, down from 59% a year earlier, attributed to higher costs in service and product gross margins [11] - Adjusted EBITDA for 2025 declined to $5.0 million from $22.4 million in the previous year [5][14] Installed Base and Product Performance - Cytek expanded its global installed base by 208 instruments in Q4, ending 2025 with 3,664 units installed [7] - The launch of the Cytek Aurora Evo system contributed to a 21% unit growth in the Aurora category in Q4 [7] Recurring Revenue and Reagents - Recurring revenue represented 34% of total revenue for 2025, increasing 21% year-over-year [9] - Reagent revenue grew more than 20% in Q4 and over 25% for the full year, driven by initiatives such as faster delivery times and a larger catalog [8] Cash Position and Share Buybacks - Cytek ended 2025 with $261.5 million in cash and equivalents, with a slight negative free cash flow of -$0.2 million in Q4 [15] - The company repurchased approximately $15.1 million of stock during 2025, representing about 3.3 million shares [15] Future Outlook - The company expects continued strong growth in service and reagents but anticipates only modest growth in instruments [17] - Management plans to invest commercially in segments where the company is currently weak, including enhancements to the reagent sales force [17]

Summary of Cytek Biosciences FY Conference Call Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Life Science Tools and Diagnostics - **Focus**: Flow cytometry technology and related services Key Points Market Performance and Growth - **Revenue Growth**: 85% of the business is experiencing double-digit growth, particularly in service, reagents, and instrument sectors, excluding Europe [2][4] - **Geographical Insights**: - **Asia-Pacific**: Expected to continue strong growth [2] - **US Market**: Stabilizing with positive revenue growth in Q3 [2] - **Europe**: Facing contraction due to previous market conditions, but signs of recovery are anticipated [2][20] Technology and Competitive Advantage - **Innovative Approach**: Cytek leverages advancements from the telecommunications sector to enhance flow cytometry, marking a significant shift in the industry [3][4] - **Product Leadership**: Cytek has deployed over 3,000 instruments, establishing itself as a leader in full spectral flow cytometry technology [4][31] - **Aurora Evo Instrument**: - Features include nanoparticle detection, automated shutdown, and remote operation, designed to meet pharmaceutical needs [12][13] - High throughput and productivity enhancements are expected to drive adoption and revenue growth [14][10] Funding Landscape and Market Dynamics - **NIH Funding**: Academic customers are diversifying funding sources; only one-third of sales are directly linked to NIH funding [6][5] - **Pharma Market Trends**: - Instrument sales in Europe saw a pause after significant growth in 2023 and 2024, while the US market showed a 12% growth in biopharma [9][10] - Cytek's technology is positioned well to capitalize on the positive secular trends in the pharma sector [9] Regional Challenges and Strategies - **EMEA Market**: - Facing challenges due to government spending cuts and a slowdown in instrument sales [19][20] - Reagent growth in EMEA is strong, indicating a positive trend despite instrument sales challenges [23] - Cytek is investing in service and sales networks in EMEA to strengthen its market position [24] Revenue Streams and Future Outlook - **Consumables and Services**: - Revenue per instrument remains stable, with service revenue growing alongside the installed base [26] - Reagent growth is robust, with a year-over-year increase close to 20%, indicating strong market share gains [28][15] - **Future Opportunities**: - Potential for $200 million in reagent revenue from the existing installed base [15] - Continued investment in marketing and sales for reagents to drive future growth [27] Competitive Landscape - **Market Positioning**: Cytek maintains a strong competitive edge through a comprehensive product and service offering, including the Cytek Cloud and Panel Builder [33] - **Emerging Markets**: The Guava Muse platform targets entry-level users and is designed for convenience and mobility, expanding Cytek's reach in cost-sensitive markets [34] Conclusion Cytek Biosciences is positioned for continued growth in the life sciences tools market, driven by innovative technology, strong performance in key regions, and a focus on expanding its consumables and services. The company is navigating challenges in the EMEA market while capitalizing on opportunities in Asia-Pacific and the US.

Summary of Cytek Biosciences FY Conference Call Company Overview - **Company**: Cytek Biosciences (NasdaqGS:CTKB) - **Industry**: Life Science Tools, specifically Flow Cytometry Key Accomplishments and Performance - **2025 Performance**: Cytek has managed to navigate unexpected challenges, including export controls and funding reductions, with minimal impact on overall performance [2] - **Instrument Sales Growth**: Core Full Spectrum Profiling (FSP) instruments achieved a 3% year-over-year unit growth despite challenging market conditions [3][5] - **Market Position**: Cytek is recognized as a leader in the flow cytometry market, with its FSP technology becoming the industry standard [4][5] Technology and Product Development - **FSP Technology**: Cytek's FSP technology allows for the analysis of more than 50 colors, significantly surpassing conventional flow cytometers [4] - **Aurora Evo Launch**: The new Aurora Evo instrument was launched, incorporating features tailored to pharmaceutical needs, such as automation and support for small particle analysis [20][22] - **Clinical Market Expansion**: Cytek has received clinical clearance in China and is working towards FDA approval in the U.S. for its clinical products [36][37] Market Dynamics and Trends - **Total Addressable Market (TAM)**: The flow cytometry market has an initial TAM of $7.5 billion, with potential growth to $16 billion as applications expand [6][7] - **Funding Challenges**: The U.S. academic and government markets are experiencing funding pressures, impacting purchase decisions, but signs of stabilization are emerging [11][12] - **Regional Performance**: Strong performance in Asia-Pacific, particularly in China, with increasing market share due to Cytek's established reputation [19][13] Financial Insights - **Revenue Growth**: Service and reagent revenues grew 18% year-over-year in Q2, with a stable relationship between installed base growth and service revenue [29] - **Reagent Market Potential**: Cytek captures less than 10% of the $150 million annual reagent market, with strategies in place to accelerate adoption [30][31] - **Guidance for 2025**: The company expects growth in the range of -2% to +2%, with confidence stemming from strong performance in Asia-Pacific and service sectors [42][43] Competitive Landscape - **Market Competition**: The shift towards full spectrum technology has led to increased competition, but Cytek views this as an endorsement of its leadership rather than a threat [39][40] - **Pricing Strategy**: Cytek maintains a cost-efficient approach, focusing on performance rather than pricing as the primary driver for customer selection [40] Long-term Growth Outlook - **Future Opportunities**: Cytek anticipates significant growth potential as the installed base matures and the clinical market expands [46] - **EBITDA Growth Potential**: High incremental margins on instrument sales suggest substantial EBITDA growth as top-line growth resumes [46] Conclusion - Cytek Biosciences is well-positioned in the flow cytometry market, with innovative technology, a strong market presence, and a clear strategy for growth despite current challenges. The company is focused on expanding its product offerings and market share while navigating funding pressures in key regions.